NG11-2 Phase-Ib Dose Escalation Phase Completes & Dose Expansion Cohort Open to Enrolment

A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer

4th March 2024 VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, has successfully completed the Dose Escalation part of their Phase-1b study, which uses NG11-2 mouthwash once daily prior to each fractional radiotherapy to reduce and prevent severe Radiation-Induced Oral Mucositis (RIOM), a well-known and debilitating side-effect of radiotherapy on patients undergoing treatment for head & neck cancer.

The Safety Committee reviewed the available data and agreed that the highest dose level remained well tolerated and that no Dose Limiting Toxicities had been reported in any of the 4 cohorts through which the NG11-2 doses had been escalated.

The Safety Committee further reviewed the data from previous and current treatment cohorts and agreed that the safety and preliminary efficacy readouts to date support initiation of the Dose Expansion phase at the selected dose level.

Enrolment of 8 patients into the Dose Expansion cohort is now open and anticipated to complete by summer 2024.

The study is investigating the safety and preliminary efficacy of NG11-2 mouthwash for reducing and preventing severe Radiation-Induced Oral Mucositis (RIOM), a well-known and debilitating side-effect of radiotherapy on patients undergoing treatment for head & neck cancer.

Dr Ningfeng Fiona Li, CEO of VasoDynamics, said:

“We are very pleased with the continued tolerability and preliminary efficacy readout of NG11-2 and it is an exciting moment for NG11-2 to successfully progress into the Dose Expansion phase of the clinical study. We are looking forward to completing the study in H2 this year.”

For enquiries, please contact:

Dr Ningfeng Fiona Li, CEO +44 7969132263
fiona.li@vasodynamics.co.uk
Gary Bower, COO +44 7960388412
gary.bower@vasodynamics.co.uk

Notes to Editors:

About VasoDynamics

VasoDynamics is a UK-based pharmaceutical development company focused on improving the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, VasoDynamics is developing cost-effective medicines for the prevention and treatment of debilitating, and often dose-limitin,g complications of cancer therapy, such as chemotherapy and radiotherapy-induced mucositis, dermatitis and hair-loss. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculature to achieve selective protection of normal tissue during cancer treatment whilst facilitating anti-cancer therapy efficacy.